In this study, silver-decorated cerium oxide (Ag@CeO₂) nanoparticles were synthesized through a simple mixing and pyrolysis process to enhance their antioxidant and antitumor properties. The synthesis methods for Ag@CeO₂ were optimized, resulting in nanoparticles with varying antioxidant activities. Notably, the embedding of Ag nanoparticles within CeO₂ during pyrolysis significantly improved the antioxidant activity and stability of the nanoparticles, leading to enhanced antitumor effects. The Ag@CeO₂ nanoparticles exhibited strong cytotoxicity against tumor cells (MCF-7) while maintaining low toxicity toward normal cells (HUVECs). These properties, combined with their ability to modulate mitochondrial membrane potential, position Ag@CeO₂ as a promising candidate for electrochemical therapy (ECT). This study highlights the antioxidant potential and the potential of Ag@CeO₂ nanoparticles in tumor treatment and provides new insights into the application of nanomaterials in ECT.

Colorectal tumor differentially expressed (CRNDE) is specifically expressed in human brains and is the most highly expressed lncRNA in gliomas. Nevertheless, its implications in low grade glioma (LGG) are still indistinct. This study presented systematic analyses of CRNDE in LGG biology. We retrospectively retrieved TCGA, CGGC and GSE16011 LGG cohorts. Survival analysis was conducted for evaluating the prognostic significance of CRNDE in LGG. A CRNDE-based nomogram was established, and its predictive performance was verified. Signaling pathways underlying CRNDE were analyzed through ssGSEA and GSEA approaches. The abundance of immune cells and activity of cancer-immunity cycle were estimated with ssGSEA approach. Immune checkpoints, HLAs, chemokines, and immunotherapeutic response indicators (TIDE, and TMB) was quantified. U251 and SW1088 cells were transfected with specific shRNAs of CRNDE, and flow cytometry (apoptosis) and western blot (β-catenin and Wnt5a) assays were conducted. Up-regulated CRNDE was found in LGG, and was linked to unfavorable clinical outcomes. The CRNDE-based nomogram enabled to accurately predict patients’ prognosis. High CRNDE expression was linked to more genomic variations, activity of tumorigenic pathways, tumor immunity (increase in infiltration of immune cells, expression of immune checkpoints, HLAs and chemokines, and cancer-immunity cycle), and therapeutic sensitivity. CRNDE knockdown mitigated malignant phenotypes of LGG cells. Our study determined CRNDE as a novel predictor for patient prognosis, tumor immunity and therapeutic response in LGG. Assessment of CRNDE expression is a promising approach for predicting the therapeutic benefits of LGG patients.

Immunoblockade therapy based on PD-1 checkpoint has shown remarkable progress in various tumors, but its effectiveness in glioma patients is still lacking.